💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent business, reasonably priced.
Shilpa Medicare is scored on the pharma / healthcare framework. It keeps a healthy 15.7% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.41× reported profit. Free cash flow is worth about 0.1% of its market value.
Book value has grown 14%/yr. Return on equity is a healthy 12.1%. In the latest quarter profit fell 6% versus the prior quarter.
At 76× earnings, the stock sits at the 29th percentile of its own 2.6-year range — the middle of where it has historically traded. Today's price already implies ~23%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 55.44 | — | — |
| P/B | 6.68 | 4.1 | worse |
| EV/EBITDA | 33.15 | 19.33 | worse |
| ROE | 12.05 | — | — |
| ROCE | 12.23 | 14.41 | worse |
| ROA | 8.03 | 1.64 | better |
| Quick Ratio | 0.88 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 13% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
1 of the 4 years shown had a loss — profitability is inconsistent. The latest year saw a +211% swing — check if it's a one-off or structural.
Operating margin has expanded from -4% to 19% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 9% — modest; the capital isn't working hard. Capital efficiency improving — ROE up 11pp across the window.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (176% vs 84%) — share dilution is eroding per-share value. 84% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.4× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 7% sequentially — momentum is building. Run-rate stepping up — recent quarters average 16% above earlier ones.
Quarterly net margins are expanding (12% → 22%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.6y median.
Promoters at 40.1% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.